Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (6)

ProteinN (2)

NSP16 (1)

NSP5 (1)

ORF1ab (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 61 - 67 records in total 67
    records per page




    A retrospective study of the clinical characteristics of COVID-19 MESHD infection in 26 children

    Authors: Anjue Tang; Wenhui Xu; min shen; Peifen Chen; Guobao Li; Yingxia Liu; Lei Liu

    doi:10.1101/2020.03.08.20029710 Date: 2020-03-10 Source: medRxiv

    Background: The outbreak of novel coronavirus pneumonia MESHD in China began in December 2019. Studies on novel coronavirus disease MESHD ( COVID-19 MESHD) were less based on pediatric patients. This study aimed to reveal the clinical characteristics of COVID-19 MESHD in children. Method: This study retrospectively analyzed the clinical symptoms, laboratory results, chest CT, and treatment of children with laboratory-confirmed COVID-19 MESHD(ie, with samples that were positive for 2019 novel coronavirus[2019-nCoV]) who were admitted to Shenzhen Center of National Infectious Disease MESHD Clinical Medical Research from January 16 to February 8, 2020. Result: Nine patients had no obvious clinical symptom. 11 patients developed fever MESHD. Other symptoms, including cough(in eleven of seventeen patients), rhinorrhea MESHD(in two), diarrhea MESHD(in two), vomiting MESHD(in two), were also observed. A small minority of patients had lymphocytopenia MESHD. Alanine transaminase or transaminase increased in three cases. According to chest CT scan, 11 patients showed unilateral pneumonia MESHD, 8 patients had no pulmonary infiltration. No serious complications such as acute respiratory syndrome MESHD and acute lung injury MESHD occurred in all patients. Conclusion: The clinical characteristics of 2019-nCoV infection MESHD in children were different from adult. The overall condition of children were mild and have a good prognosis.

    COVID-19 MESHD early warning score: a multi-parameter screening tool to identify highly suspected patients

    Authors: Cong-Ying Song; Jia Xu; Jian-Qin He; Yuan-Qiang Lu

    doi:10.1101/2020.03.05.20031906 Date: 2020-03-08 Source: medRxiv

    BACKGROUND Corona Virus Disease MESHD 2019 ( COVID-19 MESHD) is spreading worldwide. Effective screening for patients is important to limit the epidemic. However, some defects make the currently applied diagnosis methods are still not very ideal for early warning of patients. We aimed to develop a diagnostic model that allows for the quick screening of highly suspected patients using easy-to-get variables. METHODS A total of 1,311 patients receiving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleicacid detection were included, whom with a positive result were classified into COVID-19 MESHD group. Multivariate logistic regression analyses were performed to construct the diagnostic model. Receiver operating characteristic (ROC) curve analysis were used for model validation. RESULTS After analysis, signs of pneumonia MESHD on CT, history of close contact, fever MESHD, neutrophil-to-lymphocyte ratio (NLR), Tmax and sex were included in the diagnostic model. Age and meaningful respiratory symptoms were enrolled into COVID-19 MESHD early warning score ( COVID-19 MESHD EWS). The areas under the ROC curve (AUROC) indicated that both of the diagnostic model (training dataset 0.956 [95%CI 0.935-0.977, P < 0.001]; validation dataset 0.960 [95%CI 0.919-1.0, P < 0.001] ) and COVID-19 MESHD EWS (training dataset 0.956 [95%CI 0.934-0.978, P < 0.001] ; validate dataset 0.966 [95%CI 0.929-1, P < 0.001]) had good discrimination capacity. In addition, we also obtained the cut-off values of disease severity predictors, such as CT score, CD8+ T cell count, CD4+ T cell count, and so on. CONCLUSIONS The new developed COVID-19 MESHD EWS HGNC was a considerable tool for early and relatively accurately warning of SARS-CoV-2 infected MESHD patients.

    Clinical features and outcomes of 221 patients with COVID-19 MESHD in Wuhan, China

    Authors: Guqin Zhang; Chang Hu; Linjie Luo; Fang Fang; Yongfeng Chen; Jianguo Li; Zhiyong Peng; Huaqin Pan

    doi:10.1101/2020.03.02.20030452 Date: 2020-03-06 Source: medRxiv

    Rationale: In late December 2019, an outbreak of acute respiratory illness MESHD, now officially named as COVID-19 MESHD, or coronavirus disease 2019 MESHD, emerged in Wuhan, China, now spreading across the whole country and world. More data were needed to understand the clinical characteristics of the disease. Objectives: To study the epidemiology, clinical features and outcomes of patients with COVID-19 MESHD. Methods: we performed a single center, retrospective case series study in 221 patients with laboratory confirmed SARS-CoV-2 pneumonia MESHD at a university hospital. Measurements and Main Results: The median age was 55.0 years and 48.9% were male and only 8 (3.6%) patients had a history of exposure to the Huanan Seafood Market. Compared to the non-severe pneumonia MESHD patients, the median age of the severe patients was significantly older, and they were more likely to have chronic comorbidities. Most common symptoms in severe patients were high fever, anorexia MESHD and dyspnea MESHD. On admission, 33.0% patients showed leukopenia MESHD and 73.8% showed lymphopenia MESHD. In addition, the severe patients suffered a higher rate of co-infections MESHD with bacteria or fungus MESHD and they were more likely to developing complications. As of February 15, 2020, 19.0% patients had been discharged and 5.4% patients died. 80% of severe cases received ICU care, and 52.3% of them transferred to the general wards due to relieved symptoms, and the mortality rate of severe patients in ICU was 20.5%. Conclusions: The COVID-19 MESHD epidemic spreads rapidly by human-to-human transmission. Patients with elder age, chronic comorbidities, blood leukocyte/lymphocyte count, procalcitonin level, co-infection MESHD and severe complications might increase the risk of poor clinical outcomes. Keywords: coronavirus disease 2019 MESHD; clinical features; outcomes; severe patients

    Clinical Features of COVID-19 MESHD Related Liver Damage

    Authors: Zhenyu Fan; Liping Chen; Jun Li; Cheng Tian; Yajun Zhang; Shaoping Huang; Zhanju Liu; Jilin Cheng

    doi:10.1101/2020.02.26.20026971 Date: 2020-02-27 Source: medRxiv

    BACKGROUND: A recent outbreak of SARS-CoV-2 infection MESHD occurs mainly in China, with rapidly increasing the number of cases (namely COVID-19 MESHD). Abnormal liver functions MESHD are frequently present in these patients, here we aimed to clarify the clinical features of COVID-19 MESHD-related liver damage to provide some references for the clinical treatment. METHODS: In this retrospective, single-center study, we included all confirmed COVID-19 MESHD cases in Shanghai Public Health Clinical Center from January 20 to January 31, 2020. The outcomes were followed up until February 19, 2020. A total of 148 cases were analyzed for clinical features, laboratory parameters (including liver function tests), medications and the length of stay. FINDINGS: Of 148 confirmed SARS-CoV-2-infected MESHD patients, 49.3% were females and 50.7% were males. The median age was 50.5 years (interquartile range, 36-64). Patients had clinical manifestations of fever MESHD (70.1%), cough (45.3%), expectoration (26.7%) at admission. 75 patients (50.7%) showed abnormal liver functions at admission. Patients (n = 75) who had elevated liver function index were more likely to have a moderate-high degree fever MESHD (44% vs 27.4%; p = 0.035) and significantly present in male patients (62.67% vs 38.36%; p = 0.005). The numbers of CD4 HGNC+ and CD8 HGNC+ T cells were significantly lower in abnormal liver function group than those in normal liver function group. There was no statistical difference in prehospital medications between normal and abnormal liver function groups, while the utilization rate of lopinavir/ritonavir after admission was significantly higher in patients with emerging liver injury MESHD than that in patients with normal liver functions. Importantly, the emerging abnormal liver functions MESHD after admission caused a prolonged length of stay. INTERPRETATION: SARS-CoV-2 may cause the liver function damage MESHD and the Lopinavir/ritonavir should be applied carefully for the treatment of COVID-19 MESHD.

    Neurological Manifestations of Hospitalized Patients with COVID-19 MESHD in Wuhan, China: a retrospective case series study

    Authors: Ling Mao; Mengdie Wang; Shanghai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Yanan Li; Huijuan Jin; Bo Hu

    doi:10.1101/2020.02.22.20026500 Date: 2020-02-25 Source: medRxiv

    OBJECTIVE: To study the neurological manifestations of patients with coronavirus disease 2019 MESHD ( COVID-19 MESHD). DESIGN: Retrospective case series SETTING: Three designated COVID-19 MESHD care hospitals of the Union Hospital of Huazhong University of Science and Technology in Wuhan, China. PARTICIPANTS: Two hundred fourteen hospitalized patients with laboratory confirmed diagnosis of severe acute respiratory syndrome MESHD from coronavirus 2 (SARS-CoV-2) infection MESHD. Data were collected from 16 January 2020 to 19 February 2020. MAIN OUTCOME MEASURES: Clinical data were extracted from electronic medical records and reviewed by a trained team of physicians. Neurological symptoms fall into three categories: central nervous system (CNS) symptoms or diseases ( headache MESHD, dizziness MESHD, impaired consciousness MESHD, ataxia MESHD, acute cerebrovascular disease MESHD, and epilepsy MESHD), peripheral nervous system (PNS) symptoms ( hypogeusia MESHD, hyposmia, hypopsia, and neuralgia MESHD), and skeletal muscular symptoms. Data of all neurological symptoms were checked by two trained neurologists. RESULTS: Of 214 patients studied, 88 (41.1%) were severe and 126 (58.9%) were non-severe patients. Compared with non-severe patients, severe patients were older (58.7 {+/-} 15.0 years vs 48.9 {+/-} 14.7 years), had more underlying disorders (42 [47.7%] vs 41 [32.5%]), especially hypertension MESHD (32 [36.4%] vs 19 [15.1%]), and showed less typical symptoms such as fever MESHD (40 [45.5%] vs 92 [73%]) and cough (30 [34.1%] vs 77 [61.1%]). Seventy-eight (36.4%) patients had neurologic manifestations. More severe patients were likely to have neurologic symptoms (40 [45.5%] vs 38 [30.2%]), such as acute cerebrovascular diseases MESHD (5 [5.7%] vs 1 [0.8%]), impaired consciousness MESHD (13 [14.8%] vs 3 [2.4%]) and skeletal muscle injury MESHD (17 [19.3%] vs 6 [4.8%]). CONCLUSION: Compared with non-severe patients with COVID-19 MESHD, severe patients commonly had neurologic symptoms manifested as acute cerebrovascular diseases MESHD, consciousness impairment and skeletal muscle symptoms MESHD.

    Rapid colorimetric detection of COVID-19 MESHD coronavirus using a reverse tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic plat-form: iLACO

    Authors: Lin Yu; Shanshan Wu; Xiaowen Hao; Xuelong Li; Xiyang Liu; Shenglong Ye; Heng Han; Xue Dong; Xin Li; Jiyao Li; Jianmin Liu; Na Liu; Wanzhong Zhang; Vicent Pelechano; Wei-Hua Chen; Xiushan Yin

    doi:10.1101/2020.02.20.20025874 Date: 2020-02-24 Source: medRxiv

    The recent outbreak of a novel coronavirus SARS-CoV-2 MESHD (also known as 2019-nCoV) threatens global health, given serious cause for concern. SARS-CoV-2 is a human-to-human pathogen that caused fever MESHD, severe respiratory disease MESHD and pneumonia MESHD (known as COVID-19 MESHD). By press time, more than 70,000 infected people had been confirmed worldwide. SARS-CoV-2 is very similar to the severe acute respiratory syndrome MESHD (SARS) coronavirus broke out 17 years ago. However, it has increased transmissibility as compared with the SARS-CoV, e.g. very often infected individuals without any symptoms could still transfer the virus to others. It is thus urgent to develop a rapid, accurate and onsite diagnosis methods in order to effectively identify these early infects MESHD, treat them on time and control the disease spreading. Here we developed an isothermal LAMP based method-iLACO (isothermal LAMP based method for COVID-19 MESHD) to amplify a fragment of the ORF1ab PROTEIN gene using 6 primers. We assured the species-specificity of iLACO by comparing the sequences of 11 related viruses by BLAST (including 7 similar coronaviruses, 2 influenza viruses and 2 normal coronaviruses). The sensitivity is comparable to Taqman based qPCR detection method, detecting synthesized RNA equivalent to 10 copies of 2019-nCoV virus. Reaction time varied from 15-40 minutes, depending on the loading of virus in the collected samples. The accuracy, simplicity and versatility of the new developed method suggests that iLACO assays can be conveniently applied with for 2019-nCoV threat control, even in those cases where specialized molecular biology equipment is not available.

    Clinical characteristics of 51 patients discharged from hospital with COVID-19 MESHD in Chongqing,China

    Authors: liu lei; Gao Jian-ya

    doi:10.1101/2020.02.20.20025536 Date: 2020-02-23 Source: medRxiv

    Abstract BackgroundSince December 2019, Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)-infected disease MESHD ( Coronavirus Disease 2019 MESHD COVID-19 MESHD) emerged in Wuhan , Chinaand rapidly spread throughout Chinaeven throughout the world. We try to describe the epidemiological and clinical characteristics of COVID-19 MESHD in non-Wuhan areaand explore its effective treatment. MethodsRetrospective, single-center case series of the 51 hospitalized patients with confirmed COVID-19 MESHD at Chongqing University Three Gorges Hospital in Chongqing, China, from January 20 to February 3, 2020The discharge time was from January 29 to February 11, 2020. The main results and indicators of epidemiology, demography, clinical manifestation, laboratory examination, imaging data and treatment data of 51 patients with covid-19 MESHD were collected and analyzed. The changes of blood routine and biochemical indexes at discharge and admission were compared. Compare the clinical characteristics of severe patients (including severe and critical patients) and non- severe patients (general patients). Results Of 51 hospitalized patients with COVID-19 MESHD, the median age was 45 years (interquartile range, 34-51; range, 16-68 years) and 32 (62.7%) were men.43(84.3%)patients had been to Wuhan or Other Hubei areas outside Wuhanand 4(7.7%) patients had a clear contact history of COVID-19 MESHD patients before the onset of the disease, and 4(7.7%) patients had no clear epidemiological history of COVID-19 MESHD.Common symptoms included fever MESHD (43 [84.3%]), cough (38 [74.5%]) and fatigue MESHD (22 [43.1%]). Lymphopenia MESHD was observed in 26 patients (51.0%), and elevated C-reactive protein HGNC level in 32 patients (62.7%). Ground-glass opacity was the typical radiological finding on chest computed tomography (41 [80.4%])Local consolidation of pneumonia MESHD in some patients(17 [33.3%]).Most of the patients were treated with traditional Chinese medicine decoction (28 [54.9%])all of them received aerosol inhalation of recombinant human interferon a-1b for injection and oral antiviral therapy with Lopinavir and Ritonavir tablets (51 [100%]); Most of the patients were given Bacillus licheniformis capsules regulated intestinal flora treatment (44 [86.3%]). 10 patients (19.6%) received short-term (3-5 days) glucocorticoid treatment. Compared with non-severe patients (n = 44), severe patients (n = 7) were older (median age, 52 years vs 44 years), had a higher proportion of diabetes mellitus (4 [57.1%] vs 0 [0.0%]), most of them needed antibiotic treatment (7 [100%] vs 4 [9.1%], most of them needed nutritional diet (6 [85.7%) vs 0 [0.0%], and were more likely to have dyspnea (6 [85.7%] vs 5 [11.4%])most of them needed noninvasive mechanical ventilation (6 [85.7%] vs 0 [0.0%]). Except one patient died, the remaining 50 patients were discharged according to the discharge standard, the common clinical symptoms disappeared basically, the lymphocyte increased significantly (P=0.008), CRP HGNC decreased significantly (P <0.001). The median length of stay was 12 days (IQR, 9-13). ConclusionIn 51 single center cases confirmed as COVID-19 MESHD and discharged from the hospital, 13.7% of the patients were severe. The main clinical symptoms of patients with COVID-19 MESHD were fever, cough and astheniaSome patients had obvious dyspnea. They had clinical laboratory and radiologic characteristics. There is no specific drug treatment for the disease. For the treatment of COVID-19 MESHD, in addition to oxygen inhalation and antiviral treatment, attention should be paid to the dialectical treatment of traditional Chinese medicine, regulation of intestinal flora, nutritional support treatment and other comprehensive treatment.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.